Intra-articular bone marrow mononuclear cell therapy improves lameness from naturally occurring equine osteoarthritis.
Authors: Everett J Blake, Menarim Bruno C, Barrett Sarah H, Bogers Sophie H, Byron Christopher R, Pleasant R Scott, Werre Stephen R, Dahlgren Linda A
Journal: Frontiers in veterinary science
Summary
# Editorial Summary: Intra-articular Bone Marrow Mononuclear Cell Therapy for Equine Osteoarthritis Osteoarthritis remains a significant clinical challenge in equine practice because conventional treatments provide only temporary symptom relief whilst carrying risks of adverse effects; this study investigated whether bone marrow mononuclear cells (BMNC)—a naturally occurring source of macrophage progenitors with known anti-inflammatory properties—could durably improve lameness in horses with naturally occurring, moderate OA. Thirty-two horses with radiographically confirmed OA in a single joint received either saline (control), triamcinolone (positive control), or intra-articular BMNC injection, with lameness assessed subjectively and objectively, joint circumference measured, and synovial fluid sampled at 0, 7, and 21 days post-injection. The BMNC-treated group showed significant improvements in objective lameness scores between days 7 and 21, whilst joint circumference decreased significantly from day 7 onwards and remained significantly lower than saline controls at day 21; notably, no adverse effects were observed in any group. Synovial fluid analysis revealed an expected increase in nucleated cells in the BMNC group at day 7, though inflammatory cytokine profiles showed only inconsistent differences between groups, suggesting the anti-inflammatory mechanism may not be solely cytokine-mediated. These findings support progressing to larger-scale trials, as BMNC therapy demonstrates clinical benefit without documented harm—potentially offering equine practitioners a safer alternative to corticosteroid-based approaches for managing moderate OA.
Read the full abstract on PubMed
Practical Takeaways
- •BMNC therapy appears safe and shows promise for reducing lameness and joint swelling in horses with moderate OA, with improvements visible within 3 weeks
- •Clinical improvements in lameness and joint circumference occur despite inconsistent synovial biomarker changes, suggesting the mechanism may involve cell-mediated anti-inflammatory effects rather than detectable cytokine shifts
- •This approach warrants larger clinical trials as it demonstrated benefit comparable to or potentially exceeding corticosteroid injection without noted adverse effects
Key Findings
- •Intra-articular BMNC injection significantly improved objective lameness between days 7-21 post-injection in horses with moderate OA
- •Joint circumference decreased significantly in BMNC-treated group from day 7 to 21 and was significantly lower than saline control at day 21
- •BMNC treatment resulted in elevated synovial fluid total nucleated cell count on day 7 (median 440 cells/uL) with no adverse effects in any treatment group
- •Synovial cytokine/growth factor profiles showed limited detectable differences between treatment groups despite clinical improvements in BMNC group